Mechanisms of dihydromyricetin against hepatocellular carcinoma elucidated by network pharmacology combined with experimental validation

References

• Bentzen SM. 2006. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 6(9):702–713. doi: 10.1038/nrc1950.
   PubMed Web of Science ®Google Scholar
• Brabletz T, Kalluri R, Nieto MA, Weinberg RA. 2018. EMT in cancer. Nat Rev Cancer. 18(2):128–134. doi: 10.1038/nrc.2017.118.
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Hicks BM, Hughes C, Murray LJ. 2014. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol. 32(28):3177–3183. doi: 10.1200/JCO.2013.54.4569.
   PubMed Web of Science ®Google Scholar
• Dong S, Zhu M, Wang K, Zhao X, Hu L, Jing W, Lu H, Wang S. 2021. Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism. Pharmacol Res. 171:105767. doi: 10.1016/j.phrs.2021.105767.
   PubMed Web of Science ®Google Scholar
• Gao X, Lowry PR, Zhou X, Depry C, Wei Z, Wong GW, Zhang J. 2011. PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains. Proc Natl Acad Sci U S A. 108(35):14509–14514. doi: 10.1073/pnas.1019386108.
   PubMed Web of Science ®Google Scholar
• Greenlee JD, Subramanian T, Liu K, King MR. 2021. Rafting down the metastatic cascade: the role of lipid rafts in cancer metastasis, cell death, and clinical outcomes. Cancer Res. 81(1):5–17. doi: 10.1158/0008-5472.CAN-20-2199.
   PubMed Web of Science ®Google Scholar
• Guo Y, Pan W, Liu S, Shen Z, Xu Y, Hu L. 2020. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 19(3):1997–2007. doi: 10.3892/etm.2020.8454.
   PubMed Web of Science ®Google Scholar
• Guo D, Zhang D, Ren M, Lu G, Zhang X, He S, Li Y. 2020. THBS4 promotes HCC progression by regulating ITGB1 via FAK/PI3K/AKT pathway. Faseb J. 34(8):10668–10681. doi: 10.1096/fj.202000043R.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. CELL. 144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Hryniewicz-Jankowska A, Augoff K, Sikorski AF. 2019. The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer. Exp Biol Med (Maywood). 244(13):1053–1061. doi: 10.1177/1535370219870771.
   PubMed Web of Science ®Google Scholar
• Huang H, Hu M, Zhao R, Li P, Li M. 2013. Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway. Oncol Rep. 30(5):2467–2475. doi: 10.3892/or.2013.2705.
   PubMed Web of Science ®Google Scholar
• Huang C, Su C, Wang P, Lu Y, Ho Y, Yang S, Hsin C, Lin C. 2022. Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases-2 expression in human nasopharyngeal carcinoma through extracellular signal-regulated kinase signaling pathway. Environ Toxicol. 37(5):1244–1253. doi: 10.1002/tox.23480.
   PubMed Web of Science ®Google Scholar
• Jiang L, Zhang Q, Ren H, Ma S, Lu C, Liu B, Liu J, Liang J, Li M, Zhu R. 2015. Dihydromyricetin enhances the chemo-sensitivity of nedaplatin via regulation of the p53/Bcl-2 pathway in hepatocellular carcinoma cells. PLoS One. 10(4):e124994. doi: 10.1371/journal.pone.0124994.
   Web of Science ®Google Scholar
• Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S, Matsuzawa Y, Tarui S. 1990. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res. 50(11):3270–3273.
   PubMed Web of Science ®Google Scholar
• Kuzu OF, Noory MA, Robertson GP. 2016. The role of cholesterol in cancer. Cancer Res. 76(8):2063–2070. doi: 10.1158/0008-5472.CAN-15-2613.
   PubMed Web of Science ®Google Scholar
• Li M, Tang Y, Wang D, Zhai X, Shen H, Zhong C, Yao M, Jin A, Zhou Z, Zhou S, et al. 2022. Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma. Mol Ther. 30(2):703–713. doi: 10.1016/j.ymthe.2021.09.012.
   PubMed Web of Science ®Google Scholar
• Lingwood D, Simons K. 2010. Lipid rafts as a membrane-organizing principle. Science. 327(5961):46–50. doi: 10.1126/science.1174621.
   PubMed Web of Science ®Google Scholar
• Liu D, Mao Y, Ding L, Zeng X. 2019. Dihydromyricetin: a review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability. Trends Food Sci Technol. 91:586–597. doi: 10.1016/j.tifs.2019.07.038.
   PubMed Web of Science ®Google Scholar
• Liu J, Shu Y, Zhang Q, Liu B, Xia J, Qiu M, Miao H, Li M, Zhu R. 2014. Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells. Oncol Lett. 8(4):1645–1651. doi: 10.3892/ol.2014.2330.
   PubMed Web of Science ®Google Scholar
• Liu B, Tan X, Liang J, Wu S, Liu J, Zhang Q, Zhu R. 2014. A reduction in reactive oxygen species contributes to dihydromyricetin-induced apoptosis in human hepatocellular carcinoma cells. Sci Rep. 4:7041. doi: 10.1038/srep07041.
   PubMed Web of Science ®Google Scholar
• Liu F, Tian T, Zhang Z, Xie S, Yang J, Zhu L, Wang W, Shi C, Sang L, Guo K, et al. 2022. Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma. Nat Metab. 4(8):1022–1040. doi: 10.1038/s42255-022-00616-7.
   PubMedGoogle Scholar
• Lu C, He Y, Yuan W, Xiang L, Zhang J, Liang Y, Duan J, He Y, Li M. 2017. Dihydromyricetin-mediated inhibition of the Notch1 pathway induces apoptosis in QGY7701 and HepG2 hepatoma cells. World J Gastroenterol. 23(34):6242–6251. doi: 10.3748/wjg.v23.i34.6242.
   PubMed Web of Science ®Google Scholar
• Luo J, Yang H, Song B. 2020. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 21(4):225–245. doi: 10.1038/s41580-019-0190-7.
   PubMed Web of Science ®Google Scholar
• Mok EHK, Leung CON, Zhou L, Lei MML, Leung HW, Tong M, Wong TL, Lau EYT, Ng IOL, Ding J, et al. 2022. Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma. Cancer Res. 82(17):3102–3115. doi: 10.1158/0008-5472.CAN-21-2934.
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. 2012. Statin use and reduced cancer-related mortality. N Engl J Med. 367(19):1792–1802. doi: 10.1056/NEJMoa1201735.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han K-H, Chawla YK, Shiina S, et al. 2017. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 11(4):317–370. doi: 10.1007/s12072-017-9799-9.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45(4):529–538. doi: 10.1016/j.jhep.2006.05.013.
   PubMed Web of Science ®Google Scholar
• Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. 2017. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. IJMS. 18(2):461. doi: 10.3390/ijms18020461.
   Web of Science ®Google Scholar
• Recondo G, Che J, Jänne PA, Awad MM. 2020. Targeting MET dysregulation in cancer. Cancer Discov. 10(7):922–934. doi: 10.1158/2159-8290.CD-19-1446.
   PubMed Web of Science ®Google Scholar
• Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, et al. 2018. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 392(10159):1736–1788. doi: 10.1016/S0140-6736(18)32203-7.
   PubMed Web of Science ®Google Scholar
• Shoukat S, Zheng D, Yusuf SW. 2019. Cardiotoxicity related to radiation therapy. Cardiol Clin. 37(4):449–458. doi: 10.1016/j.ccl.2019.07.010.
   PubMed Web of Science ®Google Scholar
• Silva J, Yu X, Moradian R, Folk C, Spatz MH, Kim P, Bhatti AA, Davies DL, Liang J. 2020. Dihydromyricetin protects the liver via changes in lipid metabolism and enhanced ethanol metabolism. Alcohol Clin Exp Res. 44(5):1046–1060. doi: 10.1111/acer.14326.
   PubMed Web of Science ®Google Scholar
• Smith B, Land H. 2012. Anticancer activity of the cholesterol exporter ABCA1 gene. Cell Rep. 2(3):580–590. doi: 10.1016/j.celrep.2012.08.011.
   PubMed Web of Science ®Google Scholar
• Snaebjornsson MT, Janaki-Raman S, Schulze A. 2020. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. 31(1):62–76. doi: 10.1016/j.cmet.2019.11.010.
   PubMed Web of Science ®Google Scholar
• Song Y, Sun L, Ma P, Xu L, Xiao P. 2022. Dihydromyricetin prevents obesity via regulating bile acid metabolism associated with the farnesoid X receptor in ob/ob mice. Food Funct. 13(5):2491–2503. doi: 10.1039/d1fo03971g.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al. 2020. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 5:87.
   PubMed Web of Science ®Google Scholar
• Tang W, Zhou J, Yang W, Feng Y, Wu H, Mok MTS, Zhang L, Liang Z, Liu X, Xiong Z, et al. 2022. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell Mol Immunol. 19(7):834–847. doi: 10.1038/s41423-022-00872-3.
   PubMed Web of Science ®Google Scholar
• Tomas A, Futter CE, Eden ER. 2014. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 24(1):26–34. doi: 10.1016/j.tcb.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB, Wouters A, et al. 2020. The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. 60:41–56. doi: 10.1016/j.semcancer.2019.10.002.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Li X, Xion X, Wang J, Zhou Z, Zhu X, Gu Y, Dominissini D, He L, et al. 2021. N (1)-Methyladenosine methylation in tRNA drives liver tumorigenesis by regulating cholesterol metabolism. Nat Commun. 12(1):6314. doi: 10.1038/s41467-021-26718-6.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang S, Chan HF, Lu H, Lin Z, He C, Chen M. 2017. Dihydromyricetin induces apoptosis and reverses drug resistance in ovarian cancer cells by p53-mediated downregulation of survivin. Sci Rep. 7:46060. doi: 10.1038/srep46060.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang Y, Liu J, Qu J, Hu X, Zhang F, Zheng H, Qu X, Liu Y. 2012. TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. Eur J Cancer. 48(17):3288–3299. doi: 10.1016/j.ejca.2012.03.005.
   PubMed Web of Science ®Google Scholar
• Yang JD, Roberts LR. 2010. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 7(8):448–458. doi: 10.1038/nrgastro.2010.100.
   PubMed Web of Science ®Google Scholar
• Ye L, Yin G, Jiang M, Tu B, Li Z, Wang Y. 2021. Dihydromyricetin exhibits antitumor activity in nasopharyngeal cancer cell through antagonizing Wnt/β-catenin signaling. Integr Cancer Ther. 20:153473542199121. doi: 10.1177/1534735421991217.
   Web of Science ®Google Scholar
• Zeng Y, Peng Y, Tang K, Wang YQ, Zhao ZY, Wei XY, Xu XL. 2018. Dihydromyricetin ameliorates foam cell formation via LXRα-ABCA1/ABCG1-dependent cholesterol efflux in macrophages. Biomed Pharmacother. 101:543–552. doi: 10.1016/j.biopha.2018.02.124.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li R, Zeng G, Liu B, Liu J, Shu Y, Liu Z, Qiu Z, Wang D, Miao H, et al. 2014. Dihydromyricetin inhibits migration and invasion of hepatoma cells through regulation of MMP-9 expression. World J Gastroenterol. 20(29):10082–10093. doi: 10.3748/wjg.v20.i29.10082.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang L, Peng L, Tian X, Qiu X, Cao H, Yang Q, Liao R, Yan F. 2019. Dihydromyricetin protects HUVECs of oxidative damage induced by sodium nitroprusside through activating PI3K/Akt/FoxO3a signalling pathway. J Cell Mol Med. 23(7):4829–4838. doi: 10.1111/jcmm.14406.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhu N, Long J, Wu H, Wang Y, Liu B, Liao D, Qin L. 2021. Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma. Acta Pharmacol Sin. 42(9):1472–1485. doi: 10.1038/s41401-020-00572-6.
   PubMed Web of Science ®Google Scholar
• Zhao T, Guo B, Xiao C, Chen J, Lü C, Fang F, Li B. 2021. Aerobic exercise suppresses hepatocellular carcinoma by downregulating dynamin-related protein 1 through PI3K/AKT pathway. J Integr Med. 19(5):418–427. doi: 10.1016/j.joim.2021.08.003.
   PubMedGoogle Scholar
• Zhou F, Sun X. 2021. Cholesterol metabolism: a double-edged sword in hepatocellular carcinoma. Front Cell Dev Biol. 9:762828. doi: 10.3389/fcell.2021.762828.
   PubMed Web of Science ®Google Scholar